Biohaven Ltd. (BHVN) is a Healthcare · Biotechnology company listed on NYSE. Price $13.83 (-0.43%), Market cap $1.28B, 52-week low–high $7.79 ~ $18.11.
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorde
Financial statements, price targets, institutional (13F) holdings and related news for Biohaven Ltd. are updated in real time on BlackAll Trade.
Biohaven Ltd. trades at $13.83 (-0.43%). Real-time quotes and charts are available on BlackAll Trade.
Biohaven Ltd. has a market cap of about $1.28B.
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develo